# First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

> **NCT05599945** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers
- Hepatic Steatosis

## Interventions

- **DRUG:** NNC0581-0001
- **DRUG:** Placebo (NNC0581-0001)

## Key facts

- **NCT ID:** NCT05599945
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-23
- **Primary completion:** 2025-08-29
- **Final completion:** 2025-08-29
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599945, "First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05599945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*